186 related articles for article (PubMed ID: 37202806)
1. Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response.
Yan J; Deng XL; Ma SQ; Hui Li Y; Gao YM; Shi GT; Wang HS
BMC Complement Med Ther; 2023 May; 23(1):160. PubMed ID: 37202806
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
Yan J; Gao YM; Deng XL; Wang HS; Shi GT
BMC Cancer; 2023 Nov; 23(1):1161. PubMed ID: 38017425
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
5. Cantharidin induces apoptosis of H460 human lung cancer cells through mitochondria-dependent pathways.
Hsia TC; Yu CC; Hsu SC; Tang NY; Lu HF; Huang YP; Wu SH; Lin JG; Chung JG
Int J Oncol; 2014 Jul; 45(1):245-54. PubMed ID: 24818581
[TBL] [Abstract][Full Text] [Related]
6. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
7. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
8. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
9. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
10. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
12. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
13. SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma.
Lin J; Yan J; Deng XL; Wang CS; Wang HS
BMC Gastroenterol; 2023 Jan; 23(1):8. PubMed ID: 36631750
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
16. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
17. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
18. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of CTD-2547G23.4 in hepatocellular carcinoma tissues and its prospective molecular regulatory mechanism: a novel qRT-PCR and bioinformatics analysis study.
Wen DY; Lin P; Liang HW; Yang X; Li HY; He Y; Yang H; Chen G
Cancer Cell Int; 2018; 18():74. PubMed ID: 29780284
[TBL] [Abstract][Full Text] [Related]
20. Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathways.
Huang WW; Ko SW; Tsai HY; Chung JG; Chiang JH; Chen KT; Chen YC; Chen HY; Chen YF; Yang JS
Int J Oncol; 2011 Apr; 38(4):1067-73. PubMed ID: 21271215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
